Armetheon closes $24 million Series B financing

Menlo Park, CA – February 5, 2015 – Armetheon, Inc., a cardiovascular disease-focused, clinical stage, specialty biopharmaceutical company, today announced the successful closing of $24.3 million in Series B financing. The financing was co-led by Hercules Bioventure...

read more

Armetheon Completes $7.0 Million Series A Financing

Menlo Park, CA – August 28, 2014 --- Armetheon, Inc. (www.armetheon.com), a biopharmaceutical company focused on developing novel mid- to late-stage cardiovascular drug candidates, today announced that it has raised $7.0 million in its first round of financing. The...

read more

2014 Newsletter

In this edition: Sinusys earns FDA clearance for its Vent-Os Sinus Dilation System. Heart Metabolics is awarded Orphan Drug Designation for a medication to treat hypertrophic cardiomyopathy. Armetheon has completed a Special Protocol Assessment for its anticoagulant....

read more